WILMINGTON, N.C. – Chiltern has acquired Pacific Clinical Research, a pan-Asian contract research organization based in Singapore, the company announced on Monday.
The move allows Chiltern to offer integrated services throughout the Asia-Pacific region and strengthens in particular Chiltern’s oncology and anti-infective offerings.
Pacific Clinical Research founders Robert Teoh MD and Vonny Iskandar join the Chiltern management team as Managing Director, Asia-Pacific and Vice President, Asia-Pacific respectively.
“We have worked with Robert Teoh for many years and our two organisations have always collaborated well,” said Chiltern CEO James Esinhart and Chief Operating Officer Aize Smink in a joint statement.
“We have been looking for some time to strengthen Chiltern’s direct presence in the Asia-Pacific region, so we jumped at the opportunity to acquire Pacific and bring Robert and his team into Chiltern. We are very pleased to be able to offer customers the benefits of our merged offering with expanded access to patients and experienced research sites around Asia-Pacific.”
Financial terms were not disclosed.
The acquisition of Pacific Clinical Research comes after Chiltern’s purchase of Ockham, a specialist oncology and resourcing CRO, in July.
Building upon Chiltern’s existing operations in India, Australia, Singapore and Taiwan, the combined company now adds direct capabilities in Hong Kong, Korea, Malaysia, Philippines and Thailand.
Chiltern operates in more than 40 countries and has an office in Wilmington.
